Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.67 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 3/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7899171 | 0.91 | LIMK1 (0.56) | LIMK1LIMK2MAOAMAOBCHEK1 | |
| SCHEMBL615545 | 0.84 | MAOA (0.53) | LIMK1LIMK2MAOAMAOBCHEK1 | |
| SCHEMBL613137 | 0.82 | LIMK1 (0.68) | LIMK1LIMK2KDM4EMAPTHPGD | |
| SCHEMBL612219 | 0.80 | LIMK1 (1.00) | LIMK1LIMK2CHEK1KDM4EMAPT | |
| SCHEMBL614767 | 0.77 | LIMK1 (0.61) | LIMK1LIMK2CHEK1HPGDSMN1; SMN2 | |
| SCHEMBL31061690 | 0.77 | LIMK1 (0.61) | LIMK1LIMK2CHEK1HPGDSMN1; SMN2 | |
| SCHEMBL5879186 | 0.76 | MAOA (0.58) | MAOAMAOBCHEK1CTSVCTSL | |
| SCHEMBL11160990 | 0.76 | KIT (0.69) | MAOACHEK1TRPM8KDM4EMAPT | |
| SCHEMBL31362095 | 0.76 | KIT (0.69) | MAOACHEK1TRPM8KDM4EMAPT | |
| SCHEMBL10022322 | 0.74 | CHEK1 (0.48) | MAOAMAOBCHEK1CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604048-B2 | Pyridocarbazole type compounds and applications thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-10 | — | — | US | disclosed |
| US-20120041017-A1 | PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120041017-A1 | PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120041017-A1 | PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-02-16 | — | — | US | disclosed |
| WO-2010095042-A2 | PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF | CENTRE NATONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041017-A1 | PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF | NLN, OPA1, PYCR1 | LIMK1 2270/4885LIMK2 2037/4885MAOA 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.